Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Elaine T. Lam

Hematology Oncology | Oncology
UCHealth
University Physicians Incorporated
12605 E 16th Ave, Uchealth Anschutz Medical, 
Aurora, CO 
Accepting New Patients
Offers Telehealth

Distinguished in WT1-Related Wilms Tumor Syndromes
UCHealth
University Physicians Incorporated
12605 E 16th Ave, Uchealth Anschutz Medical, 
Aurora, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Elaine Lam is a Hematologist Oncology specialist and an Oncologist in Aurora, Colorado. Dr. Lam is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Chromophobe Renal Cell Carcinoma, Nephrectomy, and Tissue Biopsy. Dr. Lam is currently accepting new patients.

Her clinical research consists of co-authoring 83 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in CO
Hospital Affiliations
Uch-Memorial Health System
Uchealth Highlands Ranch Hospital
University Of Colorado Hospital Authority
Uchealth Broomfield Hospital
Longs Peak Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Denver Health Medical Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

UNIVERSITY PHYSICIANS INCORPORATED
12605 E 16th Ave, Uchealth Anschutz Medical, Aurora, CO 80045
Call: 720-848-0000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


10 Clinical Trials

A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Drug, Biological
Study Drugs: Axitinib, Nivolumab
Study Phase: Phase 2
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
An Open Label, Randomized, Phase II Trial of Metabolic Complications in Patients Treated With Enzalutamide vs Standard ADT for the Treatment of Hormone Sensitive Prostate Cancer
An Open Label, Randomized, Phase II Trial of Metabolic Complications in Patients Treated With Enzalutamide vs Standard ADT for the Treatment of Hormone Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drugs: Enzalutamide, Leuprolide acetate, Goserelin acetate, Histrelin acetate, Triptorelin, Degarelix
Study Phase: Phase 2
Phase I/II Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
Phase I/II Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Cabozantinib, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drugs: SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab
Study Phase: Phase 1
A Phase II Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
A Phase II Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: April 29, 2024
Intervention Type: Drug
Study Drug: TAK-228
Study Phase: Phase 2
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
Enrollment Status: Unknown
Publish Date: March 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: March 17, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

83 Total Publications

Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study.
Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study.
Journal: ESMO open
Published: April 21, 2025
View All 83 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sofyan M. Radaideh
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sofyan M. Radaideh
Hematology Oncology | Hematology | Oncology

Rocky Mountain Cancer Centers Llp

1800 Williams St, Suite 200, 
Denver, CO 
 (6.6 miles away)
303-388-4876
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sofyan Radaideh is a Hematologist Oncology specialist and a Hematologist in Denver, Colorado. Dr. Radaideh is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Neuroendocrine Tumor, Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, and Chronic B-Cell Leukemia (CBCL).

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Nauman Moazzam
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Nauman Moazzam
Hematology Oncology | Hematology | Oncology

Rocky Mountain Cancer Centers Llp

11750 W 2nd Place, Suite 150, 
Lakewood, CO 
 (15.4 miles away)
303-763-4020
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nauman Moazzam is a Hematologist Oncology specialist and a Hematologist in Lakewood, Colorado. Dr. Moazzam is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Chronic Familial Neutropenia, and Agranulocytosis.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Manojkumar Bupathi
Hematology Oncology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Manojkumar Bupathi
Hematology Oncology | Oncology

Rocky Mountain Cancer Centers Llp

22 W Dry Creek Circle, 
Littleton, CO 
 (13.7 miles away)
303-730-4700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Manojkumar Bupathi is a Hematologist Oncology specialist and an Oncologist in Littleton, Colorado. Dr. Bupathi is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Urothelial Cancer, Breast Cancer, Paget Disease of the Breast, and Chromophobe Renal Cell Carcinoma.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lam's expertise for a condition
ConditionClose
  • Elite
  • Renal Cell Carcinoma (RCC)
    Dr. Lam is
    Elite
    . Learn about Renal Cell Carcinoma (RCC).
    See more Renal Cell Carcinoma (RCC) experts
  • Distinguished
  • Adult Soft Tissue Sarcoma
    Dr. Lam is
    Distinguished
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Chromophobe Renal Cell Carcinoma
    Dr. Lam is
    Distinguished
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Clear Cell Sarcoma
    Dr. Lam is
    Distinguished
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Familial Prostate Cancer
    Dr. Lam is
    Distinguished
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Familial Wilms Tumor 2
    Dr. Lam is
    Distinguished
    . Learn about Familial Wilms Tumor 2.
    See more Familial Wilms Tumor 2 experts
  • Muscle Invasive Bladder Cancer
    Dr. Lam is
    Distinguished
    . Learn about Muscle Invasive Bladder Cancer.
    See more Muscle Invasive Bladder Cancer experts
View All 10 Distinguished Conditions
  • Advanced
  • Bladder Cancer
    Dr. Lam is
    Advanced
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Choriocarcinoma
    Dr. Lam is
    Advanced
    . Learn about Choriocarcinoma.
    See more Choriocarcinoma experts
  • Cowden Syndrome
    Dr. Lam is
    Advanced
    . Learn about Cowden Syndrome.
    See more Cowden Syndrome experts
  • Hypothalamic Hamartomas
    Dr. Lam is
    Advanced
    . Learn about Hypothalamic Hamartomas.
    See more Hypothalamic Hamartomas experts
  • Linear Nevus Sebaceous Syndrome
    Dr. Lam is
    Advanced
    . Learn about Linear Nevus Sebaceous Syndrome.
    See more Linear Nevus Sebaceous Syndrome experts
  • Peutz-Jeghers Syndrome
    Dr. Lam is
    Advanced
    . Learn about Peutz-Jeghers Syndrome.
    See more Peutz-Jeghers Syndrome experts
View All 16 Advanced Conditions
  • Experienced
  • Bone Tumor
    Dr. Lam is
    Experienced
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Caffey Disease
    Dr. Lam is
    Experienced
    . Learn about Caffey Disease.
    See more Caffey Disease experts
  • Dehydration
    Dr. Lam is
    Experienced
    . Learn about Dehydration.
    See more Dehydration experts
  • Hypophosphatemia
    Dr. Lam is
    Experienced
    . Learn about Hypophosphatemia.
    See more Hypophosphatemia experts
  • Interstitial Nephritis
    Dr. Lam is
    Experienced
    . Learn about Interstitial Nephritis.
    See more Interstitial Nephritis experts
  • Juvenile Primary Osteoporosis
    Dr. Lam is
    Experienced
    . Learn about Juvenile Primary Osteoporosis.
    See more Juvenile Primary Osteoporosis experts
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved